1-20 of 47
Jacob Laubach
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase II Study of Isatuximab, Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (The SKylaRk Trial)

Elizabeth K. O'Donnell, Clifton C. Mo, Andrew J. Yee, Omar Nadeem, Andrew R. Branagan, Jacob Laubach, Jacalyn Rosenblatt, Nora Horick, Paul G. Richardson, Noopur Raje, Diana Cirstea
Journal: Blood
Blood (2023) 142 (Supplement 1): 4671.
https://doi.org/10.1182/blood-2023-181019
Published: 2023
Journal Articles

Phase II Trial of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Omar Nadeem, Sophie Magidson, Robert A. Redd, Jacob Laubach, Clifton C. Mo, Elizabeth K. O'Donnell, Adam S. Sperling, Monique A Hartley-Brown, Shonali Midha, Marjorie Marto, Christine Davie, Caroline Ricciardi, Dechen Choden, Ashlee Strutevant, Jillian Alberti, Lorenzo Trippa, Nikhil C Munshi, Kenneth C. Anderson, Paul G. Richardson, Irene M. Ghobrial
Journal: Blood
Blood (2023) 142 (Supplement 1): 3382.
https://doi.org/10.1182/blood-2023-177947
Published: 2023
Journal Articles

Immuno-PRISM: A Randomized Phase II Platform Study of Bispecific Antibodies in High-Risk Smoldering Myeloma

Omar Nadeem, Sophie Magidson, Shonali Midha, Elizabeth K. O'Donnell, Monique A Hartley-Brown, Adam S. Sperling, Robert A. Redd, Marjorie Marto, Christine Davie, Caroline Ricciardi, Dechen Choden, Ashlee Strutevant, Jillian Alberti, Clifton C. Mo, Jacob Laubach, Paul G. Richardson, Kenneth C. Anderson, Nikhil C Munshi, Lorenzo Trippa, Irene M. Ghobrial
Journal: Blood
Blood (2023) 142 (Supplement 1): 206.
https://doi.org/10.1182/blood-2023-177954
Published: 2023
Journal Articles

Venetoclax in Combination with Daratumumab and Dexamethasone Elicits Deep, Durable Responses in Patients with t(11;14) Relapsed/Refractory Multiple Myeloma: Updated Analyses of Minimal Residual Disease Negativity in Phase 1/2 Study

Nizar J Bahlis, Hang Quach, Rachid Baz, Annette J. Vangsted, Shir-Jing Ho, Niels Abildgaard, Jacob Laubach, Vincent Ribrag, Peter M. Voorhees, Xifeng Wang, Orlando Bueno, Yan Luo, Jeremy A Ross, Jonathan L. Kaufman
Journal: Blood
Blood (2023) 142 (Supplement 1): 338.
https://doi.org/10.1182/blood-2023-180766
Published: 2023
Journal Articles

Expansion, Persistence, and Characteristics of Autologous, Bhv-1100 Armored Memory-like NK Cells Infused Prior to Autologous Stem Cell Transplant in MRD+ Multiple Myeloma Patients: A First-in-Human Trial

Grace Caroline Birch, Juliana Vergara-Cadavid, Mohsin Maqbool, Alba Martini, Khanlinh Dinh, Roman M. Shapiro, Michela Ansuinelli, Tuyet Nguyen, Carol Reynolds, Im Soo Y, Hope Wei, Sarah Hogan, Elizabeth Kendricken, Adam S. Sperling, Omar Nadeem, Jacob Laubach, Alissa Rybicki, Steven Schnittman, Elyse Stock, Diego Hernandez Rodriguez, Heather Daley, Sarah Nikiforow, Jerome Ritz, Robert J. Soiffer, Giada Bianchi, Rizwan Romee
Journal: Blood
Blood (2023) 142 (Supplement 1): 2105.
https://doi.org/10.1182/blood-2023-180224
Published: 2023
Journal Articles

Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone: Patient Reported Outcomes from GRIFFIN

Rebecca Silbermann, Jacob Laubach, Jonathan L. Kaufman, Douglas W. Sborov, Brandi Reeves, Cesar Rodriguez, Ajai Chari, Luciano J. Costa, Larry D. Anderson, Jr., Nitya Nathwani, Nina Shah, Naresh Bumma, Sarah A. Holstein, Caitlin Costello, Andrzej Jakubowiak, Robert Z. Orlowski, Kenneth H. Shain, Andrew J. Cowan, Katharine S. Gries, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S. Lin, Paul G. Richardson, Saad Usmani, Peter M. Voorhees
Journal: Blood
Blood (2022) 140 (Supplement 1): 1146–1149.
https://doi.org/10.1182/blood-2022-162313
Published: 2022
Journal Articles

Keeping an Eye on Belantamab: Characterizing Ocular Toxicities

Shahrier Hossain, Omar Marzouk, Houry Leblebjian, Robert A. Redd, Jacob Laubach
Journal: Blood
Blood (2022) 140 (Supplement 1): 13206–13207.
https://doi.org/10.1182/blood-2022-166720
Published: 2022
Journal Articles

A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Omar Nadeem, Robert A. Redd, Trevor J. Bayliss, Peter Barth, Jacob Laubach, Clifton C. Mo, Giada Bianchi, Kelly Masone, Kyle Griffin, Lindsay Issokson, Anna Barrell, Randi Doherty, Deborah Mailand, Alexandra Distaso, Sarah Patches, Kathryn Goodrich, Kathleen Oneill, Vaishali Sanchorawala, Leyla O. Shune, Paul G. Richardson
Journal: Blood
Blood (2022) 140 (Supplement 1): 10180–10181.
https://doi.org/10.1182/blood-2022-165512
Published: 2022
Journal Articles

A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (The SKylaRk Trial)

Elizabeth K. O'Donnell, Clifton C Mo, Omar Nadeem, Andrew J. Yee, Andrew R. Branagan, Jacob Laubach, Marilyn T. Gammon, Kathleen J. Lively, Lisette Packer, Cynthia C. Harrington, Emerentia Agyemang, Jacalyn Rosenblatt, Nora K. Horick, Paul G. Richardson, Noopur Raje
Journal: Blood
Blood (2022) 140 (Supplement 1): 7282–7283.
https://doi.org/10.1182/blood-2022-156328
Published: 2022
Journal Articles

Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial

Clinical Trials & Observations
Peter M. Voorhees, Jonathan L. Kaufman, Jacob Laubach, Douglas W. Sborov, Brandi Reeves, Cesar Rodriguez, Ajai Chari, Rebecca Silbermann, Luciano J. Costa, Larry D. Anderson, Jr, Nitya Nathwani, Nina Shah, Yvonne A. Efebera, Sarah A. Holstein, Caitlin Costello, Andrzej Jakubowiak, Tanya M. Wildes, Robert Z. Orlowski, Kenneth H. Shain, Andrew J. Cowan, Sean Murphy, Yana Lutska, Huiling Pei, Jon Ukropec, Jessica Vermeulen, Carla de Boer, Daniela Hoehn, Thomas S. Lin, Paul G. Richardson
Journal: Blood
Blood (2020) 136 (8): 936–945.
https://doi.org/10.1182/blood.2020005288
Published: 2020
Includes: Supplemental data
Journal Articles

Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Chia-jen Liu, MD, Irene M. Ghobrial, MD, Mark Bustoros, MD, Kaitlen Reyes, NP, Kalvis Hornburg, BA, Ashraf Z. Badros, MD, James J. Vredenburgh, MD, Adam Boruchov, MD, Jeffrey V Matous, MD, Aaron Caola, BS, Bradley Rivotto, BS, Alexandra Savell, BS, Patrick Henrick, BS, Claudia E. Paba-Prada, MD, Robert L. Schlossman, MD, Jacob Laubach, MD, Jacalyn Rosenblatt, MD, Andrew J Yee, MD, Omar Nadeem, MD, Rodrigo O. Maegawa, MD, Andrzej Jakubowiak, MD PhD, Saad Z. Usmani, MD, Manisha Bhutani, MD, Joseph Cappuccio, BS, Brianna Berrios, BS, Kimberly Noonan, NP, Oksana Zavidij, PhD, Tarek H Mouhieddine, MD, Cody J Boehner, Carl-Jannes Neuse, Karma Ziad Salem, MD, Mairead Reidy, PhD, Jihye Park, PhD, Michael Agius, PhD, Mahshid Rahmat, PhD, Salomon Manier, MD PhD, Divaya Bhutani, MD, Jeffrey A Zonder, MD, Nikhil Munshi, MD, Daniel Auclair, PhD, Kenneth Anderson, MD, Paul Richardson
Journal: Blood
Blood (2018) 132 (Supplement 1): 154.
https://doi.org/10.1182/blood-2018-154
Published: 2018
Journal Articles

Evaluation of Infusion Reactions in Patients Receiving Daratumumab Post-Implementation of an Augmented Pre- and Peri-Medication Regimen

Patrick McBride, PharmD, Houry Leblebjian, PharmD, Paul Richardson, Jacob Laubach, MD, Hillary Prescott, PharmD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3234.
https://doi.org/10.1182/blood-2018-99-111361
Published: 2018
Journal Articles

A Phase Ib/II Study of the Novel Anti-CXCR4 Antibody Ulocuplumab (BMS-936564) in Combination with Lenalidomide Plus Low-Dose Dexamethasone, or with Bortezomib Plus Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma

Irene M. Ghobrial, MD, Chia-Jen Liu, MD PhD, Raymond P. Perez, MD, Paul Richardson, Kenneth C. Anderson, MD, Jacob Laubach, MD, Patrick Henrick, BS, Alexandra Savell, BS, Kaitlen Reyes, NP, Kalvis Hornburg, BA, Stacey Chuma, BSN, Peter Sabbatini, Pamela S. Becker, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3263.
https://doi.org/10.1182/blood-2018-99-117773
Published: 2018
Journal Articles

Improving Rates of Venous Thromboembolism Prophylaxis in Multiple Myeloma Patients on Immunomodulatory Drugs

Houry Leblebjian, PharmD, Joanna Hamilton, MA, MS, Sydney Smith, PharmD, Jacob Laubach, MD, Nancy Berliner, MD, Aric Parnes, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2235.
https://doi.org/10.1182/blood-2018-99-115436
Published: 2018
Journal Articles

A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RVD) Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma: Promising Activity and Manageable Toxicity, Including in High Risk Disease

Jacob Laubach, MD, Andrew J Yee, MD, Jacalyn Rosenblatt, MD, Jeffrey V Matous, MD, Charles M. Farber, MDPhD, Thomas H. Openshaw, MD, Rodrigo O. Maegawa, MD, Michaela L. Tsai, MD, Irene M. Ghobrial, MD, Giada Bianchi, MD, Bhupendra Rawal, MS, Heidi Dipietro, RN, Kristen Cummings, RN, John Harran, RN, Peter O'Gorman, MD PhD FRCP, FRCPath, Kathleen Scott, PhD, Kathleen Fitzpatrick, Jennifer Abovich, Hannah Baker, Alexandra Savell, BS, Joshua Hansen, Paul Richardson
Journal: Blood
Blood (2018) 132 (Supplement 1): 1981.
https://doi.org/10.1182/blood-2018-99-116280
Published: 2018
Journal Articles

Evaluation of Re-Intensification of Daratumumab to Weekly or Biweekly Dosing Schedule

Elaine Xiang, PharmD, Hillary Prescott, PharmD, Jacob Laubach, MD, Paul Richardson, Kaitlen Reyes, NP, Irene M. Ghobrial, MD, Houry Leblebjian, PharmD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2024.
https://doi.org/10.1182/blood-2018-99-111191
Published: 2018
Journal Articles

The Role of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Multiple Myeloma: Immunomodulator Maintenance Post Autologous Stem Cell Transplant (ASCT) Predicts Better Outcome

Tarek H Mouhieddine, MD, Jihye Park, PhD, Robert A. Redd, MS, Christopher J. Gibson, MD, Salomon Manier, MD PhD, Amin H Nassar, MD, Marzia Capelletti, PhD, Daisy Huynh, MS, Mark Bustoros, MD, Romanos Sklavenitis-Pistofidis, MD, Kalvis Hornburg, BA, Henry Dumke, BS, Muhieddine M Itani, MD, Cody J Boehner, Chia-Jen Liu, MD PhD, Saud H AlDubayan, MD, Brendan Reardon, Eliezer Van Allen, MD, Daniel Auclair, PhD, Robert L. Schlossman, MD, Nikhil Munshi, MD, Kenneth Anderson, MD, David P. Steensma, MD, Jacob Laubach, MD, Paul Richardson, Jerome Ritz, MD PhD, Benjamin L. Ebert, MDPhD, Robert J. Soiffer, MD, Donna S Neuberg, ScD, Irene M. Ghobrial, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 749.
https://doi.org/10.1182/blood-2018-99-113059
Published: 2018
Journal Articles

CRISPR-Based Functional Genomics Studies Reveal Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins: Implications for Novel Therapeutics across Diverse Neoplasias

Ryosuke Shirasaki, MD PhD, Sara Gandolfi, MD, Ricardo De Matos Simoes, PhD, Geoffrey Matthews, PhD, Dennis Buckley, Olga Dashevsky, PhD, Sondra L. Downey-Kopyscinski, PhD, Huihui Tang, PhD, Michal Sheffer, PhD, Eugen Dhimolea, PhD, Brian Glassner, PhD, Megan Bariteau, BSc, Jeffrey Sorrell, BA, Johanna B Bruggenthies, Quinlan Sievers, BA, Haley Poarch, Nicholas P Kwiatkowski, PhD, Tinghu Zhang, PhD, Jacob Laubach, MD, Robert L. Schlossman, MD, Paul Richardson, Aedin Culhane, PhD, Richard WJ Groen, PhD, Eric S. Fischer, PhD, Francisca Vazquez, PhD, Aviad Tsherniak, PhD, William C. Hahn, MD PhD, Joan Levy, Daniel Auclair, PhD, Jonathan D. Licht, MD, Jonathan J Keats, PhD, Lawrence H. Boise, PhD, Benjamin L. Ebert, MDPhD, James Bradner, MD, Nathanae Gray, PhD, Constantine S. Mitsiades, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1367.
https://doi.org/10.1182/blood-2018-99-116232
Published: 2018
Journal Articles

Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Mark Bustoros, MD, Chia-jen Liu, MD, Kaitlen Reyes, NP, Kalvis Hornburg, BA, Kathleen Guimond, RN, Rachel Styles, Alexandra Savell, BS, Brianna Berrios, BS, Diane Warren, Henry Dumke, BS, Bradley Rivotto, BS, Patrick Henrick, BS, Emily Scranton, NP, Houry Leblebjian, PharmD, Kirsten Meid, MPH, Robert L. Schlossman, MD, Nikhil Munshi, MD, Jacob Laubach, MD, Kenneth C. Anderson, MD, Paul Richardson, Irene M. Ghobrial, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 804.
https://doi.org/10.1182/blood-2018-99-117871
Published: 2018
Journal Articles

Impact of Bone Marrow Biopsy on Risk Stratification of Low-Risk IgG MGUS Patients

Mark Bustoros, Eftathios Kastritis, Chia-Jen Liu, MD PhD, Nikolaos Kanellias, David Liu, MD MPH, MS, Maria Gavriatopoulou, Adriana Perilla Glen, Maria Roussou, Patrick Henrick, BS, Magdalini Migkou, Alexandra Savell, BS, Kimberly Noonan, NP, Kaitlen Reyes, NP, Bradley Rivotto, BS, Houry Leblebjian, PharmD, Claudia Paba-Prada, MD, Dimitrios C. Ziogas, Jacob Laubach, MD, Robert L. Schlossman, MD, Kenneth C Anderson, MD, Paul G Richardson, MD, Irene M Ghobrial, MD, Meletios A. Dimopoulos
Journal: Blood
Blood (2017) 130 (Supplement 1): 5397.
https://doi.org/10.1182/blood.V130.Suppl_1.5397.5397
Published: 2017